SEC Company Response from Q (QCLS) — Dec 13, 2017
Q/C TECHNOLOGIES, INC. (QCLS) (CIK 0001321834)
Date: Dec. 13, 2017 · CIK: 0001321834 · Accession: 0001213900-17-013210
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-221746
Letter
AKERS BIOSCIENCES, INC.
GROVE ROAD
THOROFARE, NJ 08086
December 13, 2017
VIA EDGAR
U.S. Securities & Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Irene Paik
Re:
Akers Biosciences, Inc.
Registration Statement on Form S-1
File No. 333-221746
Ladies and Gentlemen:
In accordance with Rule 461 of the Securities Act of 1933, as amended, Akers Biosciences, Inc. (the “Company”) hereby respectfully requests that the effective date of the above-captioned Registration Statement (the “Filing”) be accelerated so that it will be declared effective at 5:00 p.m. Eastern Time on Thursday, December 14, 2017, or as soon thereafter as possible.
* * * *
Very Truly Yours,
Akers Biosciences, Inc.
Show Raw Text
CORRESP
1
filename1.htm
AKERS
BIOSCIENCES, INC.
201
GROVE ROAD
THOROFARE,
NJ 08086
December
13, 2017
VIA
EDGAR
U.S. Securities & Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Irene Paik
Re:
Akers
Biosciences, Inc.
Registration
Statement on Form S-1
File No. 333-221746
Ladies and Gentlemen:
In accordance with Rule 461 of the Securities
Act of 1933, as amended, Akers Biosciences, Inc. (the “Company”) hereby respectfully requests that the effective date
of the above-captioned Registration Statement (the “Filing”) be accelerated so that it will be declared effective at
5:00 p.m. Eastern Time on Thursday, December 14, 2017, or as soon thereafter as possible.
* * * *
Very Truly Yours,
Akers Biosciences, Inc.
/s/ John J. Gormally
John J. Gormally
Chief Executive Officer